Characterization of Tumor Responses in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib in the Phase 3 Randomized Trial: REFLECT

By sjmartinez • October 22, 2024

Finn RS, Qin S, Piscaglia F, Evans TRJ, Knox JJ, López López C, Ramji Z, Ren M, Mody K, Vogel A, Kudo M. Characterization of Tumor Responses in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib in the Phase 3 Randomized Trial: REFLECT. Liver Cancer. 2024 Feb 26;13(5):537-547. doi: 10.1159/000537947. PMID: 39435271; PMCID: PMC11493383.

Tags: Hematology/Oncology, Hepatocellular carcinoma, lenvatinib, Objective response, Publications

Cell free RNA detection of pancreatic cancer in pre diagnostic high risk and symptomatic patients

Moore TW, Spiliotopoulos E, Callahan RL, Kirschbaum CW, Bailey CF, Kim HJ, Roskams-Hieter B, Goncalves F, Keith D, Grossberg AJ, Spellman PT, Mills GB, Sears[...]

US expert Delphi consensus on the prevention and management of stomatitis in patients treated with datopotamab deruxtecan

Rugo H, Bardia A, Bruno DS, Ernani V, Hamilton E, Heist R, Jhaveri K, Levy B, Lisberg A, O'Shaughnessy J, Sands J, Spira A, Tolaney[...]

Melisi D, Macarulla T, De La Fouchardière C, Pazo Cid RA, Chandana SR, Kiss I, Lee WJ, Goetze TO, Van Cutsem E, Paulson AS, Bekaii-Saab[...]